Xenon Pharmaceuticals XENE Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's operating lease right-of-use asset amortization?
- Xenon Pharmaceuticals (XENE) reported operating lease right-of-use asset amortization of $338K in Q1 2026.
- How has Xenon Pharmaceuticals's operating lease right-of-use asset amortization changed year-over-year?
- Xenon Pharmaceuticals's operating lease right-of-use asset amortization increased by 5.0% year-over-year, from $322K to $338K.
- What is the long-term trend for Xenon Pharmaceuticals's operating lease right-of-use asset amortization?
- Over 3 years (2022 to 2025), Xenon Pharmaceuticals's operating lease right-of-use asset amortization has grown at a 17.0% compound annual growth rate (CAGR), from $819K to $1.31M.